JC17 (Medicine) - Asthma and Allergic Lung Diseases Flashcards

1
Q

Define Asthma

A

Asthma: defined a chronic inflammatory disorder of airways
□ Leading to widespread but variable airflow obstruction
□ R_eversible_ either spontaneously or with treatment
□ Inflammation is a/w bronchial hyper-responsiveness to a variety of stimuli

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

4 types of asthma

A

□ Atopic asthma: individuals with tendency to atopy
→ Predisposition to synthesize IgE to common allergens
→ Hx of infantile eczema and allergic rhinitis

□ Non-atopic asthma: individuals with no evidence of atopy
→ Usually in adults
→ Often triggered by respiratory infections and inhaled air pollutants

□ Drug-induced asthma: asthma provoked by drugs (eg. aspirin)

□ Occupational asthma: provoked by occupational pollutants (eg. fumes, organic dusts)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

4 host risk factors to asthma

A

□ Genetics: certain genes with ↑risk of asthma (eg. IL-3, IL-4, TNF-α…)

□ Atopy: ↑asthma prevalence with ↑serum IgE level

□ Gender: M>F in children/young adults, F>M in adults

□ Obesity: asthma more common and difficult to control if BMI >30kg/m2
→ Obese subjects usually have poorer lung function and more co-morbidities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Environmental triggers of Asthma

A

□ Allergens:
→ Indoor: fecal pellets of house dust mites, pets, cockroaches
→ Outdoor: alternaria (a genus of Ascomycete fungi), air pollution, tobacco smoke/ second hand smoke
→ Occupational (5-15% of adult onset asthma)

□ Infection
□ Other triggers: exercise, cold air

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the T-helper cell response to Intracellular vs Extracellular pathogens

A

Naïve CD4+ T cells (Th0) activated by interaction with Ag presented by MHC-II

Further differentiation based on predominant cytokine profile

  • Th1 differentiation facilitated by IFN-γ, IL-12 → promotes cell-mediated immunity → ↑macrophage, neutrophil, CD8+ T cells activity → elimination of intracellular bacteria and viruses
  • Th2 differentiation facilitated by IL-4, IL-5 → promotes humoral immunity → ↑IgE production, mast cell and eosinophil recruitment, growth and differentiation → elimination of extracellular pathogens (eg. parasites)
  • Reciprocal inhibition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Compare Th1 vs Th2 mediated immune response

A

Naïve CD4+ T cells (Th0) activated by interaction with Ag presented by MHC-II

Th1 differentiation facilitated by IFN-γ, IL-12 → promotes cell-mediated immunity → ↑macrophage, neutrophil, CD8+ T cells activity → elimination of intracellular bacteria and viruses

Th2 differentiation facilitated by IL-4, IL-5 → promotes humoral immunity→ ↑IgE production, mast cell and eosinophil recruitment, growth and differentiation → elimination of extracellular pathogens (eg. parasites)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Explain the Hygiene Hypothesis and propensity of atopy

A

Hygiene hypothesis: proposed mechanism behind atopic tendency in some individuals

□ Childhood microbial exposure associated with ↓allergy and asthma
→ Lifestyle: ↑family size, older siblings, day care
→ Farming: animal contact, stable exposure, drinking unpasteurized farm milk
→ Animal exposure: pet keeping

□ Reason: ↓childhood Th1 activation → poor Th1 development → hyperactive Th2 system → overreaction to allergens (Type I hypersensitivity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Explain the effects of hypersensitivity reaction on airway

A

→ Bronchoconstriction due to abnormal smooth muscle response to inflammation

→ Airway inflammation due to vasogenic oedema and inflammatory infiltrate

→ Mucous hypersecretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe Type I hypersensitivity reaction against allergens

A

Atopic asthma: type I HS reaction towards allergens

Allergen exposure → Th2 response activated → IL-4 → ↑IgE production

→ binds to and sensitizes mast cells

→ further exposure to same allergen results in release of mast cell mediators (immediate phase) → IL-5

→ eosinophil activation and recruitment (delayed phase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Explain mechanism of aspirin-induced asthma

A

Aspirin-induced asthma: inhibition of cyclooxygenase → arachidonic acid shunted towards lipoxygenase pathway → ↑leukotrienes (potent bronchoconstrictors)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Explain exercise-induced asthma

A

Exercise-induced asthma: hyperventilation → water + heat loss from mucosa → lining irritated → inflammatory mediator release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the sequalae of chronic airway inflammation

A

1) Airway hyper-reactivity
2) Airway remodeling

□ Chronic inflammation results in irreversible structural changes predisposing to airflow obstruction
□ Includes:
→ Smooth muscle hyperplasia → ↑bronchoconstriction
→ Goblet cell hyperplasia → ↑mucus secretion
→ Fibrosis → airway wall thickening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Define the clinical features of asthma

  • S/S
  • Temporal pattern
  • Associated symptoms
A

Recurrent episodic attacks of wheezing, chest tightness, breathlessness, cough

Characteristically occurs following exposure (5-15min) and resolve with trigger avoidance or asthma medications

Classically with diurnal variation → worse at night or early morning

± signs of atopy: allergic rhinitis, eczema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Ddx of generalized wheeze and localized wheeze

A

D/dx of generalized wheeze:

  • COPD
  • Bronchiectasis
  • Bronchiolitis obliterans
  • Viral bronchiolitis (in children)

D/dx of localized wheeze:

  • Tumour
  • Foreign body
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Outline Diagnosis for Asthma

  • Clinical features
  • Lung Function test metrics
A

1) Predominantly clinical based on compatible Hx ± P/E

□ Hx: variable symptoms of wheezes, cough, chest tightness, SOB
□ P/E: characteristic widespread, polyphonic wheezes during attacks

2) Lung Function Test: Spirometry or Peak flow meter

≥1 instance of ↓FEV1/FVC, i.e. ≤75% in adult, ≤85% in children

≥12% and 200mL ↑FEV1 after bronchodilator or ICS

>10% diurnal variability in twice daily PEF over 1-2w

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Specific test for airway hypersensitivity

A

Airway hyper-reactivity: by bronchoprovocation test

≥20% ↓FEV1 post-methacholine/histamine at standard dose

≥15% ↓FEV1 post-hyperventilation, hypertonic saline or mannitol challenge

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Second line investigations for Asthma

A

□ Allergic status: skin prick test, total/allergen-specific IgE, serum eosinophil count

□ CXR: normal or hyperinflated ± lobar collapse (2o to mucus obstruction) → mainly to exclude alternative d/dx

□ Flow-volume loop: ‘scooped out’ concave appearance signifying diffuse intrathoracic airflow obstruction

□ Airway inflammation tests:
→ Sputum eosinophil count >2%
→ Exhaled breath NO concentration (FENO)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Characteristic spirometry graph shape for asthma

A

“Scooped out appearance”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Major Ddx of Asthma

A

COPD

asthma-COPD overlap syndrome (ACOS)

Bronchiectasis

Central airway obstruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Tests to rule out major Ddx of Asthma

A

1) COPD: Diagnosed by abnormal post-bronchodilator spirometry
2) Bronchiectasis: Diagnosed by CXR/HRCT demonstrating airway dilatation (‘tram-line’ appearance)
3) Central airway obstruction: Spirometry also shows obstructive pattern but flow volume loop is characteristic for upper airway obstruction (expiratory plateau)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Assessment of asthma control

A

Assessment of asthma control by two domains:

□ Symptom control: should have daytime asthma symptoms and reliever use ≤2×/w + no night waking + no activity limitation

□ Risk assessment: based on risk factors for exacerbation, fixed airflow limitation and medication S/E

22
Q

Assessmnet of severity of asthma

A

Severity of asthma: retrospectively from level of Tx required to control symptoms and exacerbation
□ Assessed at a few months after starting on controller Tx

□ Mild asthma: well-controlled with steps 1 or 2

□ Moderate asthma: well-controlled with step 3

□ Severe asthma: well- or poorly controlled with steps 4 or 5

23
Q

Measures to decrease house dust and mites

A
  • Encasement of mattresses, pillows and duvets with vinyl covers
  • Wash all bedding with hot water regularly every ≤2w
  • Remove carpets and stuffed toys
24
Q

Aims of asthma management

A

□ Complete control
→ No attacks, A/E visits, hospitalization
→ No or minimal symptoms
→ No limitation of activity
→ Normal or near normal lung function

□ With least medications and least S/E

25
Q

3 pillars of asthma management

A
  1. Patient education: stop smoking, weight loss…
  2. Avoidance of triggers
  3. Control-based asthma management
26
Q

Outline classes of drugs used for asthma control

A
  1. Reliever: short-acting bronchodilators → for breakthrough symptoms and preventing exercise-related symptoms
  2. Controller: should be initiated asap after diagnosis of asthma for an improvement in outcome
    → Anti-inflammatory drugs to ↓airway inflammation
    → Long-acting bronchodilators to ↓bronchoconstriction
  3. Add-on therapy: for patients with severe asthma
27
Q

Explain the principle of control-based asthma management (steps)

A

Review response and adjust treatment at 1-3mo after starting and every 3-12mo thereafter:

□ Stepping up: after reviewing alternative causes of poor control as below
□ Stepping down: considered when sustained control for >3mo + low risk of exacerbation

28
Q

List controller and reliever needed for Step 1 asthma control

A

Reliever: Low dose ICS + Formoterol

Controller: As-needed Low dose ICS + Formoterol

29
Q

List controller and reliever needed for Step 2 asthma control

A

Reliever: SABA or Low-dose ICS/ formoterol

Controller:

  • Regular low-dose ICS
  • LTRA* (alternative to ICS)
  • Low dose ICS/ LABA (same efficacy as ICS)
30
Q

List controller and reliever needed for Step 3 asthma control

A

Reliever: SABA or low dose ICS/ Formoterol

Controller:

  • Low dose ICS + formoterol
  • Medium dose ICS
  • Low dose ICS + LTRA + Theophylline SR* (C/O children)
31
Q

List controller and reliever needed for Step 4 asthma control

A

Reliever: SABA or low-dose ICS/formoterol

Controller:

  • Medium-dose ICS/LABA or low-dose ICS/formoterol (also as reliever)
  • High-dose ICS/LABA

- Theophylline SR or LTRA as add-on (C/O children)

- Tiotropium (LAMA) as add-on (C/O children)

32
Q

List reliever and controller for step 5 asthma control

A

Reliever: SABA or low-dose ICS/formoterol

Controller:

  • ICS/LABA
  • Oral maintenance corticosteroids
    • Tiotropium (LAMA)/ Omalizumab (anti-IgE)/ Anti-IL-5 as add-on
  • Mast cell stabilizers
  • Sputum-guided treatment for Eosinophil count
  • Non-pharmacological treatment: bronchial thermoplasty, high-altitude treatment, psychological interventions
33
Q

Management of patient with poor asthma control after medication

A

Inhaler use: inhaler technique, adherence and barriers to use

Other/ Alternative diagnosis: esp if variable airflow limitation has not been demonstrated

Remove exacerbators: triggers, inducers (smoking, β-blockers, NSAIDs), comorbidities (eg. rhinitis, obesity, GERD, OSA)

step up treatment

34
Q

Routes of controller and reliever administration for astham control

A

Nebulizer: use of medication solution to generate a mist for inhalation

Inhaler: different types, which MDI can be used with or without spacer

35
Q

Advantage and disadvantage of Nebulizer

A

Advantage: (1) no need hand-mouth coordination (2) Use in status asthmaticus

Disadvantage: (1) requires electricity (2) may transmit infection (3) high dose side effect

36
Q

Advantage of using a spacer with inhaler

A

Spacer: suspends aerosol inside spacer → Decrease oropharyngeal deposition of aerosol

37
Q

List 4 bronchodilator classes with examples

A
  1. Short-acting β2-agonist (SABA) e.g. salbutamol (Ventolin), terbutaline (Bricanyl)
  2. Long-acting β2-agonist (LABA) e.g. salmeterol (Serevent), formoterol (Oxis)
  3. Long-acting muscarinic antagonist (LAMA) e.g. tiotropium bromide
  4. Methylxanthines e.g. theophylline, aminophylline
38
Q

MoA and S/E of SABA

A

MoA: β2 activation → Gsα → ↑cAMP → smooth muscle relaxation

S/E: β-agonistic effects include tremor, headache, arrhythmia, hypoK

39
Q

MoA and function of LAMA

A

MoA: ↓mAChR activation → ↓Gq → ↓Ca2+ → smooth muscle relaxation

Use: as add-on therapy in step 4 onwards

S/E: Acute close angle glaucoma

40
Q

MoA and S/E of methylxanthines

A

MoA: inhibition of phosphodiesterase → ↑cAMP → SM relaxation

add-on therapy from step 3 onwards

S/E: diuresis, CNS/CVS stimulant effect, GI disturbance, unpredictable drug interactions

41
Q

List 5 anti-inflammatory drugs for asthma control with examples

A

Inhaled corticosteroids (ICS) Examples: beclomethasone (Becloforte (250μg), Beclotide (50μg)), budesonide (Pulmicort), fluticasone (Flixotide)

Leukotriene receptor antagonist (LTRA) Examples: montelukast (Singulair), zafirlukast

Anti-IgE antibody Examples: omalizumab

Anti-IL-5 therapy Examples: mepolizumab, reslizumab (anti-IL5), benralizumab (anti-IL5r)

Mast cell stabilizer Examples: cromolyn sodium, nedocromil sodium

42
Q

S/E of ICS

A

S/E: minimal systemic effect, oral candidiasis (5-10%)

→ reassure (harmless), then treat by nystatin suspension for gargle or lozenge

43
Q

MoA and use of LTRA

A

MoA: block action of leukotriene (AA derivative) → ↓bronchoconstriction

Use: as steroid-sparing therapy in mild/moderate asthma, esp effective in exercise- and aspirin-induced asthma

44
Q

MoA and use of Anti-IgE antibody

A

MoA: binds IgE → ↓activation of mast cells and basophils

Use: reserved for atopic asthma (with documented ↑IgE, +ve skin prick test)

or as steroid-sparing therapy in steroid-dependent asthma

45
Q

MoA and use of Anti-IL5 therapy

A

MoA: block action of IL-5 → ↓eosinophilic airway inflammation

Use: reserved for eosinophilic asthma with (↑serum eosinophil count)

46
Q

Example, MoA and use of Mast cell stabilizer

A

Nedocromil sodium, Sodium chromoglycate

MoA: ↓mast cell degranulation and activation + ↓exaggerated irritant receptor neuronal reflex

Use: rarely used due to limited benefit in severe asthma and ↓availability

47
Q

2 main types of inhaler

A

Metered dose inhaler - more common aerosol form with hand-eye coordination

Dry powder inhaler - breath activated powder form for poor technique, multiple inhalation per go

48
Q

Life threatening features of acute asthmatic attack

A

Silent chest
Hypotension
One-third of best/predicted PEF
Cyanosis
Confusion

49
Q

Compare presentation of Mild/ moderate to severe acute exacerbation of asthma

A

Mild:

  • Talk in phrases, prefer sitting, calm
  • Increase RR, no use of accessory muscles
  • HR 100-120, SpO2 90-95%, PEF > 50% predicted

Severe:

  • Talk in words, lean forward, agitated

- RR >30, use of accessory muscles

- HR >120, SpO2 <90%, PEF <50% predicted

50
Q

Management of mild acute exacerbation of asthma

A

Monitor vital signs, pulse oximetry, PEF/FEV1, ABG, electrolytes, CX

□ Controlled O2 therapy aiming SpO2 93-95% by nasal cannulae or mask

SABA: salbutamol 4 puffs Q4H with spacer + PRN use

Oral corticosteroids

51
Q

Management of severe acute exacerbation of asthma

A

Monitor: vital signs, pulse oximetry, PEF/FEV1, ABG, electrolytes, CXR

O2 therapy SpO2 93-95% target

SABA

Oral/ IV corticosteroids

Add-on Ipratropium bromide

52
Q

Monitoring of acute exacerbation of asthma

A

Reassessment in ALL patients 1h after initial treatment

Assess: clinical status, response to treatment, lung function measurement (PEF, FEV1)

Adjust dose of SABA and increase/ taper corticosteroid

Adjust O2 and wean after 95% O2

Discharge when PEF/FEV1 > 60% predicted